Equilibrium Solubility Determination with HPLC-UV

Equilibrium solubility stands as one of the most critical physicochemical parameters in early drug discovery and lead optimization stages, defining the maximum concentration of a lead compound that can dissolve in a defined solvent or biorelevant medium under controlled, steady-state equilibrium conditions. For most novel small-molecule leads, poor aqueous solubility is a pervasive bottleneck that directly limits downstream bioavailability, compromises pharmacological activity assessment, and increases the risk of late-stage formulation failure. Accurate, reproducible solubility data for lead candidates is not merely descriptive—it guides rational lead prioritization, early formulation feasibility evaluation, solubilization strategy design, and preclinical candidate selection, making it an indispensable decision-making tool in early pharmaceutical R&D.

PharmaAnalytica delivers a specialized, high-precision Equilibrium Solubility Determination Service for Lead Compounds, powered by validated High-Performance Liquid Chromatography with UV Detection (HPLC-UV). This service is custom-tailored for the unique constraints of early drug discovery: limited lead compound availability, rapid screening demands, and strict data reliability for lead-to-candidate progression. By combining standardized shake-flask equilibrium protocols, strict temperature-controlled incubation, and sensitive HPLC-UV quantification, we generate traceable, robust solubility data that aligns with ICH and FDA regulatory guidelines for early-stage pharmaceutical development, supporting confident lead optimization and preformulation planning.

Applications in Lead Studies

• Lead Candidate Prioritization: Screen and rank novel leads based on aqueous solubility profiles to eliminate poorly soluble candidates early and focus resources on high-feasibility molecules.
• pH-Dependent Solubility Profiling: Generate full pH-solubility curves to assess solubility across physiological pH ranges, guiding formulation design for pH-sensitive leads.
• Biorelevant Solubility Assessment: Test solubility in simulated gastric fluid (SGF), simulated intestinal fluid (SIF) and fasted-state simulated intestinal fluid (FaSSIF) to predict in vivo dissolution and oral absorption potential.
• Early Solubilization Screening: Evaluate the efficacy of safe solubilizers, co-solvents and surfactants to identify feasible solubility enhancement strategies for lead optimization.
• Physicochemical Property Characterization: Supplement lipophilicity and pKa data to build a comprehensive physicochemical profile for lead candidates, supporting ADMET prediction.

PharmaAnalytica's Technology Platform

PharmaAnalytica's Equilibrium Solubility Studies

Expert Scientific Support

In-house R&D scientists provide data interpretation and actionable formulation recommendations for lead compound progression.

Lead-Optimized Protocols

Tailored for low-volume, novel lead compounds, minimizing sample waste while ensuring full equilibrium and accurate results.

Regulatory-Ready Data Output

Complete test reports include detailed methodology, raw chromatograms, calculated solubility values, and data interpretation, fully compliant with ICH Q1A, Q6A, and USP regulatory standards for regulatory submissions.

Efficient Turnaround Time

Streamlined workflows support fast screening and data delivery, accelerating lead prioritization and optimization cycles.

In the competitive landscape of early drug discovery, eliminating solubility-related risks at the lead stage is key to reducing late-stage attrition. PharmaAnalytica's Equilibrium Solubility Determination Service for Lead Compounds (HPLC-UV) combines specialized protocols, reliable analytical instrumentation, and discovery-focused expertise to deliver the critical data you need to prioritize, optimize, and advance high-quality lead candidates efficiently.